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Broad-scale untargeted biochemical phenotyping is a technology that supplements
widely accepted assays, such as organic acid, amino acid, and acylcarnitine analyses
typically utilized for the diagnosis of inborn errors of metabolism. In this study, we
investigate the analyte changes associated with 4-aminobutyrate aminotransferase
(ABAT, GABA transaminase) deficiency and treatments that affect GABA metabolism.
GABA-transaminase deficiency is a rare neurodevelopmental and neurometabolic
disorder caused by mutations in ABAT and resulting in accumulation of GABA in the
cerebrospinal fluid (CSF). For that reason, measurement of GABA in CSF is currently
the primary approach to diagnosis. GABA-transaminase deficiency results in severe
developmental delay with intellectual disability, seizures, and movement disorder, and is
often associated with death in childhood. Using an untargeted metabolomics platform,
we analyzed EDTA plasma, urine, and CSF specimens from four individuals with GABA-
transaminase deficiency to identify biomarkers by comparing the biochemical profile
of individual patient samples to a pediatric-centric population cohort. Metabolomic
analyses of over 1,000 clinical plasma samples revealed a rich source of biochemical
information. Three out of four patients showed significantly elevated levels of the
molecule 2-pyrrolidinone (Z-score≥2) in plasma, and whole exome sequencing revealed
variants of uncertain significance in ABAT. Additionally, these same patients also had
elevated levels of succinimide in plasma, urine, and CSF and/or homocarnosine in urine
and CSF. In the analysis of clinical EDTA plasma samples, the levels of succinimide
and 2-pyrrolidinone showed a high level of correlation (R = 0.73), indicating impairment
in GABA metabolism and further supporting the association with GABA-transaminase
deficiency and the pathogenicity of the ABAT variants. Further analysis of metabolomic
data across our patient population revealed the association of elevated levels of 2-
pyrrolidinone with administration of vigabatrin, a commonly used anti-seizure medication
and a known inhibitor of GABA-transaminase. These data indicate that anti-seizure
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medications may alter the biochemical and metabolomic data, potentially impacting
the interpretation and diagnosis for the patient. Further, these data demonstrate the
power of combining broad scale genotyping and phenotyping technologies to diagnose
inherited neurometabolic disorders and support the use of metabolic phenotyping of
plasma to screen for GABA-transaminase deficiency.
Keywords: 2-pyrrolidinone, vigabatrin, GABA, neurometabolic, inborn error of metabolism, neurotransmitter, 4-
aminobutyrate aminotransferase deficiency, GABA-transaminase deficiency
INTRODUCTION
Gamma-aminobutyric acid (GABA) transaminase deficiency
(OMIM #613163), also known as 4-ABAT deficiency is a rare
genetic disorder that disrupts the degradation of GABA to
succinic semialdehyde (Figure 1). This IEM is due to decreased
or deficient activity of the enzyme 4-ABAT (ABAT, EC 2.6.1.19,
OMIM #137150). GABA-transaminase deficiency is an ultra-
rare disease reported and characterized in only a few patients
(Medina-Kauwe et al., 1998, 1999; Tsuji et al., 2010; Besse
et al., 2016; Louro et al., 2016; Koenig et al., 2017; Nagappa
et al., 2017). The few reports suggest it is much rarer than
other disorders of GABA metabolism, including glutamate
decarboxylase deficiency (OMIM 603513), SSADH deficiency
(OMIM 271980), and homocarnosinosis (serum carnosinase
deficiency) (OMIM 236130) (Jakobs et al., 1993).
GABA has a relatively short half-life in plasma, is rapidly
absorbed, and has both endocrine and hormonal effects (Abel and
McCandless, 1992; Li et al., 2015; Maguire et al., 2015). GABA
serves as the primary inhibitory neurotransmitter in the human
nervous system, and GABA metabolism to succinic semialdehyde
helps to regulate its levels and neurotransmitter activity. The
accumulation of GABA, either through enzymatic inactivity of
ABAT or medical intervention, can result in elevated levels of
2-pyrrolidinone, due to cyclization of GABA (Callery et al.,
1978). Conversely, 2-pyrrolidinone can be converted to GABA
when it is administered intravenously (Callery et al., 1979) or
orally (Fasolato et al., 1988). 2-pyrrolidinone can be converted to
succinimide through a two-step reaction (Bandle et al., 1984).
Aminobutyrate aminotransferase catalyzes the conversion of
GABA to succinic semialdehyde, which is then oxidized to
succinate by SSADH. Succinate can enter the tricarboxylic
acid cycle for NADH and FADH2 production. Inhibitors
of ABAT include valproate (Li et al., 2016; Piplani et al.,
2016), vigabatrin (Petroff et al., 1995, 1996a,b), and topiramate
(Meldrum and Rogawski, 2007; Porter et al., 2012). The
inhibition of ABAT activity results in the accumulation of
GABA, β-alanine, homocarnosine, and 2-pyrrolidinone (Jaeken
et al., 1990; Parviz et al., 2014). Increased levels of GABA
lead to symptomatic features of GABA-transaminase deficiency,
including psychomotor retardation, hypotonia, hyperreflexia,
lethargy, refractory seizures, abnormal brain magnetic resonance
imaging (MRI) and electroencephalogram (EEG) abnormalities
Abbreviations: ABAT, aminobutyrate aminotransferase; CSF, cerebrospinal fluid;
GABA, gamma-amino butyric acid; GDH, glutamate dehydrogenase; IEM, inborn
error of metabolism; LC, liquid chromatography; MS, mass spectrometry; SSADH,
succinic semialdehyde dehydrogenase.
(Pearl et al., 2009; Dracopoulos et al., 2010; Schonstedt et al.,
2015; Hussain et al., 2017). Traditional diagnostic avenues for
GABA-transaminase deficiency include enzymatic testing of
ABAT, neurotransmitter profiling of CSF – including GABA, and
molecular testing of ABAT for pathogenic variants. Biomarkers
of GABA-transaminase deficiency include elevated GABA in
CSF; however, CSF GABA may not be included in some
clinically available neurotransmitters analyses, limiting the
diagnostic utility.
As a neurometabolic disorder, GABA-transaminase deficiency
typically presents initially with hypotonia and may present with
difficult to control seizures, including infantile spasms. Seizures
can sometimes be moderated through dietary and/or medical
intervention such as ketogenic diets which can influence seizure
activity and GABA levels (Dahlin et al., 2005; Bough, 2008; Nylen
et al., 2008; Yudkoff et al., 2008; Suzuki et al., 2009; Woolf et al.,
2015; Li et al., 2017). Topiramate and vigabatrin are anti-seizure
medications utilized to treat seizure disorders including infantile
spasms. Vigabatrin is an irreversible inhibitor of ABAT that
causes increased levels of GABA in the brain (Gram et al.,
1989; Sheean et al., 1992; Petroff et al., 1999a; Kang et al., 2003;
Rogawski and Loscher, 2004). In a rat model, inhibition of ABAT
with vigabatrin resulted in decreased ABAT activity in brain, liver,
and kidney and significantly increased levels of GABA in liver,
brain, and plasma (Qume and Fowler, 1996). Reversible changes
on brain MRI including T2 hyperintensities in the basal ganglia,
brainstem and dentate nucleus have been reported in patients
taking vigabatrin for infantile spasms (Pearl et al., 2009). The
exact mechanism of action of topiramate is not known; however,
inhibition of the binding of GABA to GABA-A receptors,
resulting in increased levels of brain GABA, homocarnosine,
and 2-pyrrolidinone (Petroff et al., 1999b) has been
proposed (Meldrum and Rogawski, 2007).
Untargeted MS, also known as clinical metabolomics, can
identify compounds routinely tested in patients diagnosed with
IEMs, as well as analytes for which no clinical testing is available
in the United States (Miller et al., 2015; Kennedy et al., 2016,
2017). However, treatment with the medications topiramate
or vigabatrin also raises plasma 2-pyrrolidinone levels. While
the similarity in metabolic phenotype could interfere with the
utility of this biomarker in the detection of GABA-transaminase
deficiency, drug treatment can be discerned from patient
records (and metabolomic results), and the elevation of 2-
pyrrolidinone – whether due to GABA-transaminase deficiency
or anti-seizure medication – clearly separates these cases from
the vast majority of other clinical cases tested. Here, we
describe a broader metabolic analysis of GABA metabolites and
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FIGURE 1 | GABA metabolism pathways are altered due to GABA-transaminase deficiency and treatment affecting GABA metabolism. The entire pathway from
glutamate conversion to GABA through succinate formation is represented along with the respective enzymes for each step. Due to tissue-specific expression of the
enzymes, not all molecules are detected in each biological matrix (e.g., homocarnosine is present below the limit of detection in plasma).
demonstrate that the pattern of metabolite levels can be used
to distinguish GABA-transaminase deficiency from treatment
with topiramate and valproate that inhibit GABA-transaminase,
improving the ability to accurately screen and diagnose GABA-
transaminase deficiency.
MATERIALS AND METHODS
Sample Collection
All procedures were performed in accordance with the ethical
standards of the United States Department of Health and Human
Services and were approved by the Baylor College of Medicine
and Washington University Institutional Review Boards. All
subjects or their parents/guardians gave written informed
consent for publication in accordance with the Declaration of
Helsinki. Specimens used in this analysis were referred for
clinical metabolomic testing to our clinical biochemical genetics
laboratory. All plasma samples were isolated from whole blood
collected in EDTA-containing tubes at the site of collection and
frozen. All EDTA plasma, urine, and CSF clinical samples were
stored at−20◦C until analyzed.
Patients
Patients with a diagnosis of GABA-transaminase deficiency were
identified either as part of this analysis (Patients 3 and 4) or were
previously identified and reported (Patients 1 and 2) (Besse et al.,
2015, 2016; Koenig et al., 2017).
Case Presentations
Patient 1
A 21-month old male presented with hypotonia and global
developmental delay (Besse et al., 2016; Koenig et al., 2017).
At 21 months, he sat supported, was non-verbal but understood
“no” and could wave as a gesture to communicate goodbye. He
had intermittent upward eye deviation, diagnosed as oculomotor
apraxia, head drops, hand twitching, and continued episodes
of staring. Continuous EEG monitoring was abnormal with a
slow background and multi-focal spike and wave but without
electrographic changes with the abnormal movements. He had
delayed myelination on brain MRI at 9 months old with mild
increased T2 signal in the bilateral thalamus (Figures 2A,B).
CSF studies for neurotransmitters (excluding GABA) and amino
acids were normal. Whole exome sequencing revealed compound
heterozygous variants of uncertain significance (VUS) inherited
in trans in ABAT (c.454C > T, p.P152S and c.1393G > C,
p.G465R). Diagnosis was confirmed with CSF GABA elevated at
247 nmol/L (normal range 17–67 nmol/L).
Patient 2
Patient 2 is a 6-year old male (at the time of testing) previously
reported with GABA-transaminase (Besse et al., 2015). He
presented initially with hypotonia and vision impairment. He
had severe progressive psychomotor retardation with inability to
even hold his head, non-verbal, medically refractory intractable
seizures, and cortical visual impairment. His initial EEG
was normal early in infancy but progressed with generalized
slowing and multifocal spike and wave activity. MRI at age
17 months reported severe global atrophy involving the right
cerebral hemisphere more than left and signal abnormalities
involving bilateral internal capsules and dentate nuclei and
decreased amount of white matter, as well as delayed myelination
(Figures 2C–E). He had similarly affected sisters who died at
age 9 years and 1 year old. Whole exome sequencing revealed a
homozygous VUS in ABAT, c.631C > T (p.L211F), later shown
to result in enzyme deficiency (Besse et al., 2015).
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FIGURE 2 | (A,B) Patient 1 at 9 months old. (A) T1 axial image and (B) T2
axial image. No evidence of atrophy or injury. White arrows demarcate areas
of delayed myelination; thick arrow show abnormal hyperintensity in bilateral
thalamus. Images (C–E). Patient 2 at 17 months old. (C) Axial diffusion
weighted imaging (DWI) and (D) Axial apparent diffusion coefficient (ADC).
Severe bilateral cerebral atrophy right side (red arrows) greater than the left
side. Enlarged lateral ventricles secondary to ex vacuo loss. White arrows
demonstrate acute restricted diffusion in white matter than can be related to
acute injury. (E) Axial T2 FLAIR image with T2 hyperintensities indicated by
yellow arrow in bilateral dentate nuclei. (F,G) Patient 3, age 3 years. T2 FLAIR
axial images are shown. (F) White arrow shows T2 hyperintensities in bilateral
thalami, and (G) Yellow arrow shows T2 hyperintensities in dentate nucleus.
(H–J) Patient 4 at age 6 years. (H) Axial T1 image shows bilateral frontal
periventricular heterotopia (white arrows). (I,J) Axial FLAIR images showed
patchy hyperintensity in the thalamus (I) and midbrain (J) (white arrows).
Patient 3
Patient 3 is a 4-year old male, born by C-section due to fetal
macrosomia. Evaluation at 4 years of age revealed motor delays
(walked independently at 3 years of age) and speech delays (20–30
words), mild hypotonia, significantly ataxic gate (frequent falls),
autistic features (behavioral outbursts in unfamiliar settings,
hypersensitive to noise and aversion to anything touching his
head) and strabismus. Brain MRI revealed abnormal increased
signal in the T2 imaging in thalami, brainstem, globus pallidus,
and cerebellar dentate nuclei bilaterally, as well as in deep and
subcortical white matter (Figures 2F,G). No seizures have been
reported to this date. Whole exome sequencing identified two
variants inherited in trans in ABAT: a c.168+1G > A likely
pathogenic variant and heterozygous c.638T>G (p.F213C) VUS.
No other significant findings were present in this patient at the
time of evaluation.
Patient 4
Patient 4 is a 7-year-old female who initially presented at
age 5 months with hypotonia, failure to thrive, and global
developmental delay. Generalized chorea, characterized by
writhing movements of all limbs and tongue thrusting, emerged
between 6 and 12 months. She also developed multifocal jerky
movements suggestive of myoclonus. Her movement disorder
is partially controlled with clonazepam and levetiracetam. She
has profound developmental delay, with absent head control
and a general paucity of purposeful voluntary movements.
There is no history of clinical seizures. EEG at age 3 years
demonstrated generalized slowing, and a repeat study at
7 years showed multifocal sharp waves. Brain MRI at age
6 years demonstrated frontally predominant cerebral atrophy,
bilateral frontal periventricular nodular heterotopia, thick corpus
callosum, and abnormal areas of T2 hyperintensity in bilateral
thalami and midbrain (Figures 2H–J). The patient is the product
of a close consanguineous union. Whole exome sequencing
detected a homozygous VUS in ABAT, c.1394G > A, p.G465D.
In addition, the patient is homozygous for a VUS in LRRC7,
c.2938C > T, p.R980X. LRRC7 has not been associated with
a human disease. Diagnosis of GABA-transaminase deficiency
was confirmed with significantly elevated levels of free and total
GABA in CSF: 272 (nM) and 32.2 (µM), respectively (reference
ranges: free GABA, 32–170 nM and total GABA, 3.3–12.2 µM)
(Baylor Institute of Metabolic Disease, Dallas).
Biochemical Profiling
Metabolomic profiling was performed by Baylor Genetics
Laboratories (Houston, TX, United States) and Metabolon, Inc.,
(Morrisville, NC, United States), as described previously (Evans
et al., 2009, 2014; Miller et al., 2015) for plasma, urine (Kennedy
et al., 2016), and CSF (Kennedy et al., 2017) using two different
metabolomics platform configurations. For both configurations,
small molecules were extracted from 100 µl of sample in an 80%
methanol solution.
The first platform configuration (platform version 1) consisted
of four analyses: GC-MS, LC-MS/MS in positive mode (LCMS
Pos), LC-MS/MS in negative mode (LCMS Neg), and a LC-
MS/MS Polar method (LCMS Pol). GC-MS was performed on
bistrimethyl-silyl-trifluoroacetamide derivatized analytes using a
Trace DSQ fast-scanning single-quadrupole mass spectrometer
(Thermo Finnigan). For LC/MS Neg and LCMS Pos methods,
chromatographic separation was completed using an ACQUITY
UPLC (Waters) equipped with a Waters BEH C18 column
followed by analysis with an Orbitrap Elite high-resolution mass
spectrometer (Thermo Finnigan).
The second configuration (platform version 2) utilized the
following chromatographic methods: LCMS Neg (same as
version 1), LCMS Pol (same as version 1), and LCMS positive
ion method focusing on lipophilic compounds (LCMS Pos Lipid),
and LCMS positive ion method focusing on polar compounds
(LCMS Pos Polar).
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Comparison of the results of the analytical performance of the
two versions of the platforms showed equivalent performance
based on molecules detected on the arms of the platform,
intra- and inter-day precision, linearity, limit of detection,
and comparison to currently utilized methods. Additionally,
the reference populations and anchor matrix samples showed
equivalence as measured by the Z-score reference population
analysis. Reference cohorts for EDTA plasma, urine, and CSF
were developed from residual normal samples remaining from
pediatric patients referred to the Baylor College of Medicine
Biochemical Genetics Laboratory for metabolic screening. For
platform version 1, 190 EDTA plasma samples were profiled and
covered 725 biochemicals of known identity (named compounds;
Miller et al., 2015), 100 urine samples were profiled and
detected 663 named compounds (Kennedy et al., 2016), and
CSF from 100 samples were analyzed with the detection of
449 named compounds. For platform version 2, the EDTA
plasma reference cohort was comprised of 536 pediatric samples
and spanned 701 named compounds, and the CSF cohort
(90% pediatric) contained 79 samples in which 426 named
biochemicals were covered.
Each run day of clinical samples for analysis included four
technical replicates of anchor samples. These anchor samples
consisted a pool of plasma, urine, or CSF samples from over 100
donors each. The anchors were utilized to median normalize each
run day to compare clinical samples directly across different run
days and to the reference population database.
In both configurations, Tier 1 (Sumner et al., 2007) metabolite
identification was achieved by matching ion chromatographic
retention index, accurate mass, and mass spectral fragmentation
signatures with those of known chemical structures in a reference
library created from authentic standards measured by the
identical analytical procedure (DeHaven et al., 2010).
Statistical Analysis
Semi-quantitative analysis was achieved by comparing patient
samples to a set of invariant anchor specimens included in each
batch. Raw spectral intensity values for each biochemical were
median normalized to the anchor samples, log transformed, and
compared to a normal reference population, which consisted of
more than 1,000 unique samples, to generate Z-score values. Rare
compounds are those analytes detected in the patient specimen
but only rarely seen in the reference population (<10% of all
patients tested). Median raw intensity values were calculated
for all analytes identified in ≥2/3 of the anchor specimens and
these median values were then used to normalize corresponding
analyte raw intensity values in the patient specimen. Analytes
not identified in at least 2/3 of the anchor specimens were
excluded from analysis. Data collected from urine samples were
normalized to creatinine. Z-scores were calculated using the
TABLE 1 | Clinical demographics of patients diagnosed with GABA-transaminase deficiency.
Patient Sample
ID1
Sample
type
Age∗ Gender Ethnicity ABAT
variants+
clinical
report
Genome
(hg38)
Chromosome
16
ClinGen
canonical ID
Medications Diet
1 CSF01A
P01A
P01B
U01A
P01C
CSF
EDTA
plasma
EDTA
plasma
Urine
EDTA
plasma
15mon – 2 y Male Hispanic c.454C > T
(p.Pro152Ser)
c.1393G>C
(p.Gly465Arg)
VUS, in
trans
g.8764744C
> T
g.8781320G
> C
CA394688322
CA394691458
Milk of Magnesia,
Prevacid,
Omega-3,
Lansoprazole
Low
glutamate
2 U02A
P02A
Urine
EDTA
plasma
6 y Male Hispanic c.631C > T
(p.Leu211Phe)
homozygous
g.8768220C
> T
CA175085 Thiamine,
Levocarnitine,
Coenzyme Q10,
Keppra,
Levetiracetam,
Clonazepams
G-button
feeds
3 CSF03A
P03A
CSF
EDTA
plasma
4 y Male Caucasian c.168+1G> A,
likely
pathogenic
variant
c.638T > G
(p.Phe213Cys),
heterozygous
VUS, in
trans
g.8746099G
> A
g.8768227T
> G
CA394692408
CA394688780
No medications No special
diet
4 P04A
CSF04A
EDTA
plasma
CSF
6 y Female Caucasian c.1394G> A
(p.Gly465Asp),
VUS,
homozygous2
g.8781321G
> A
CA16607451 Miralax, Albuterol,
Keppra,
Clonazepam
G-tube
feeds with
Pediasure
1Samples in italics were analyzed on Platform version 1. All other samples were analyzed on Platform version 2. 2Other significant WES variant identified, LRRC7:
c.2938C > T (p.R980X), homozygous. +P80404, ENST00000396600. ∗y, years; mon, months.
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mean and standard deviation of the entire median-scaled log-
transformed dataset.
To compare the number of biochemicals in ABAT and non-
ABAT groups, Welch’s two-sample t-tests were used to identify
differences in numbers of biochemicals capable of distinguishing
between the GABA-transaminase deficiency and non-ABAT-
related cases on GABA-raising medications where p < 0.05 was
considered statistically significant.
RESULTS
Global biochemical profiling of EDTA plasma was performed on
six samples from four unique subjects with GABA-transaminase
deficiency (Table 1) and several subjects without variants in
ABAT taking medication that inhibits GABA-transaminase or
otherwise may alter GABA metabolism (n = 93). Urine from
two and CSF from three of the subjects were also analyzed
by global biochemical profiling (Table 1). A total of 566 ± 40
compounds was detected in ABAT EDTA plasma samples
(n = 6) versus 572 ± 32 in non-ABAT samples (n = 1,088,
not statistically significant different, p > 0.05; Supplementary
Data Sheet S1). The average plasma 2-pyrrolidinone level was
elevated by over 4.34 standard deviations (range 2.74–6.88) in
subjects with GABA-transaminase deficiency (as reported by
Z-scores) relative to a normal reference population (Table 2 and
Supplementary Data Sheet S1).
In the case of GABA-transaminase deficiency, it would be
expected that the molecules participating in reactions preceding
the defective enzyme would accumulate to higher levels than
normal/healthy levels. The pathway outlined in Figure 1 shows
the enzymes involved in GABA metabolism and the position
of GABA transaminase (ABAT) in this biological process.
For Patient 1, we analyzed EDTA plasma, urine, and CSF.
Biochemical profiling, performed at two independent time points
in plasma, showed an elevated 2-pyrrolidinone with Z-scores
of 6.16 and 6.88, respectively (Table 2 and Figures 3A, 4A).
Similar findings for 2-pyrrolidinone were observed in both CSF
(Z = 7.05) and urine (Z = 3.77) (Table 2 and Figures 3B,C). CSF
showed a succinimide level of Z = 5.76, and the urine sample for
Patient 1 had a succinimide level of Z = 4.94. For Patient 2, a urine
sample was analyzed and showed 2-pyrrolidinone levels within
the expected range of the reference population (Z = 0.69).
By the time additional samples from subsequent ABAT
patients were acquired, the configuration of the metabolomics
platform had matured. The description of the platform
configuration is outlined in the Materials and Methods section,
and Table 1 delineates which samples were run on the respective
configurations of the platform. Four plasma samples, one from
each of the four patients, were subsequently analyzed. 2-
pyrrolidinone Z-scores ranged from 1.92 to 4.73 across these
four EDTA plasma samples (Table 2). For the EDTA plasma
sample from Patient 1, succinimide showed a relative elevation
(Z = 3.83), and Z-scores for succinimide in EDTA plasma
samples from the other GABA-transaminase deficiency patients
ranged from 0.62 to 2.10 (Table 2). Of all clinical EDTA plasma
samples run on platform version 2, Z-scores were obtained
for both succinimide and 2-pyrrolidinone in 434 samples.
Correlation of the values within these samples for succinimide
and 2-pyrrolidinone showed a high degree of correlation
(R = 0.73, Figure 4B). The considerable correlation between
2-pyrrolidinone and succinimide is suggestive of a product-
substrate relationship, even though the biological mechanism
leading to the conversion of one to the other is only partially
understood (Bandle et al., 1984).
Some molecules, such as homocarnosine, are expressed in a
tissue-specific manner (Sjaastad et al., 1976). Homocarnosine is a
brain-specific dipeptide. It was not detected routinely in plasma,
most likely due to its limit of detection but did show elevated
levels in the CSF and urine of GABA-transaminase deficiency
Patients 1 and 4 (Figure 3 and Table 2).
We have seen that 2-pyrrolidinone manifested elevated levels
in patients other than those diagnosed with GABA-transaminase
deficiency. Several pharmacological interventions for seizures
were identified as part of the biochemical profile. Vigabatrin,
topiramate, levetiracetam, baclofen, and valproate treatment
TABLE 2 | Metabolomics identifies altered levels of molecules connected to GABA metabolism in GABA-transaminase deficiency patients∗.
Patient Sample Matrix 2-pyrrolidinone Succinimide Glutamate GABA Succinate Homocarnosine
1 CSF01A CSF 7.05 5.76 −1.54 0.15 1.65 2.60
U01A Urine 3.77 4.94 −0.21 0.96 0.21 1.56
P01A EDTA plasma 6.16 ND 0.71 ND 0.73 ND
P01B EDTA plasma 6.88 ND 0.86 ND −0.44 ND
P01C EDTA plasma 4.73 3.83 0.03 ND 0.40 ND
2 U02A Urine 0.69 1.55 −0.62 0.92 0.63 0.87
P02A EDTA plasma 1.92 0.62 0.92 ND 0.77 ND
3 P03A EDTA plasma 2.19 1.80 0.57 ND 1.65 ND
CSF03A CSF 5.18 1.57 −0.61 0.31 −1.28 1.91
4 P04A EDTA plasma 3.58 2.02 −0.78 ND −0.51 ND
CSF04A CSF Significant rare# 2.25 −1.15 ND −1.51 2.75
Non-GABA-T vigabatrin-treated N = 12 EDTA plasma 2.88+/−1.41 1.88+/−1.19 0.15+/−0.90 ND −1.05+/−2.16 ND
∗Z-scores are shown. ND, not detected. #Reference ranges were not definable for 2-pyrrolidinone in CSF on platform version 2. 2-pyrollidinone is considered a rare
molecule on this platform due to limited detection in the reference population; raw values are considered in the interpretation of this finding.
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FIGURE 3 | GABA metabolites are altered in GABA-transaminase deficiency and in use of treatments affecting GABA metabolism. Representative pathway images
are shown for GABA-transaminase deficiency Patient 1 in (A) EDTA Plasma, (B) Urine, and (C) CSF. Each image shows the relative accumulation of biochemicals
(red circles) or trending increases (pink circles, 1.5 ≤ Z < 2). The size of each of the circles is representative of the Z-score for that biochemical. Black circles
represent molecules with Z-scores between –1.5 and 1.5 (–1.5 < Z < 1.5). Gray circles represent biochemicals in the library but not detected in the samples using
Cytoscape to delineate biochemical pathways (http://cytoscape.org) (Shannon et al., 2003). All enzymes in the pathway are denoted by their EC designations. GDH,
glutamate dehydrogenase; SSADH, succinic semialdehyde dehydrogenase; ABAT, aminobutyrate aminotransferase; SPON; spontaneous.
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FIGURE 4 | Box plot profile for 2-pyrrolidinone levels detected in plasma for all clinical samples. (A) Z-scores for all clinical EDTA plasma samples are plotted using a
box plot format. ABAT cases show elevated Z-scores for 2-pyrrolidinone versus those patients without GABA-transaminase deficiency and treated with vigabatrin,
topiramate, and/or valproate. If patients were receiving vigabatrin in addition to other treatments, they were grouped with vigabatrin. Bars represent the mean +/– the
standard error of the mean (SEM) of the Z-scores for 2-pyrrolidinone for each group. The numbers above the bars represent the number of unique patient samples
for each group. ∗p < 0.05. NS indicates a comparison which was not statically significant, p > 0.05. (B) Correlation of 2-pyrolidinone levels to succinimide levels in
clinical plasma samples. Samples which had both 2-pyrrolidinone and succinimide Z-scored (n = 434) are plotted showing a significant positive correlation with
these two molecules.
were identified through the detection of the drugs themselves or
by metabolites of the drug intervention, e.g., 3-hydroxyvalproate
for valproate treatment. The average Z-scores for 2-pyrrolidinone
in patients with the different medications were 2.87, 0.07, 0.30,
−0.39, and −0.05 for those patients treated with vigabatrin,
levetiracetam, topiramate, baclofen, and valproate, respectively
(Figure 4A, Table 2, and Supplementary Data Sheet S2).
The average 2-pyrrolidinone Z-score for the samples from
patients diagnosed with GABA-transaminase deficiency was
4.24 (Figure 4A; Table 2). The levels of 2-pyrrolidinone
were significantly higher in patients with GABA-transaminase
deficiency and in patients treated with vigabatrin versus the
reference population (p< 0.05). The levels of 2-pyrrolidione were
not different at a statistically significant level between patients
with GABA-transaminase deficiency and patients treated with
vigabatrin (p = 0.1043).
DISCUSSION
Biochemical phenotyping, the systematic study of small-molecule
products of biochemical pathways, has been used to predict,
diagnose and monitor the effects of treatment of inborn errors
of metabolism (Atwal et al., 2015; Miller et al., 2015, 2016;
Burrage et al., 2016; Donti et al., 2016; Kennedy et al., 2016).
We applied an untargeted metabolomics profiling approach on
plasma, urine, and CSF from patients with known or suspected
GABA-transaminase deficiency and non-ABAT-related patients
treated with medications that inhibit GABA metabolism with
the objective of unraveling metabolic biomarkers to differentiate
disorder from treatment (Figures 3, 4). As with the diagnostic
and clinical utility of another neurometabolic disorder, aromatic
amino acid decarboxylase deficiency (Atwal et al., 2015), the
analysis of plasma (venipuncture) or urine is less invasive
than a lumbar puncture, less expensive, and can be performed
faster than CSF neurotransmitter analysis or DNA testing.
Collection of an appropriate and necessary volume of CSF can
be difficult, and rigorous sample handling as well as storage
protocols are required to preserve biomarkers appropriately. 2-
pyrrolidinone is an indicator of shunted GABA metabolism,
which can be affected either through inhibited ABAT activity or
through medical intervention such as topiramate or vigabatrin
which alters GABA metabolism (vigabatrin) or GABA biological
activity (topiramate).
Vigabatrin is utilized to treat seizures in SSADH deficiency,
another IEM of GABA metabolism which presents with
many of the same clinical features as GABA-transaminase
deficiency [reviewed by Vogel et al. (2013)]. Subjects with
SSADH deficiency have accumulated levels of γ-hydroxybutyric
acid (GHB) in their bloodstream and tissues and vigabatrin
treatment lowers GHB levels through GABA transaminase
inhibition (Pearl and Gropman, 2004). This inhibition is
most significant in the brain as vigabatrin has little to no
effect on peripheral GABA transaminase (Pearl et al., 1993).
In relation to other IEMs, vigabatrin treatment also down-
regulates the transcription of aromatic amino acid decarboxylase
(Buckland et al., 1996) and may drive increased levels of 3-
methoxytyrosine (Atwal et al., 2015). In our cases, vigabatrin
did not significantly alter 3-methoxytyrosine levels, but testing
additional samples may help characterize how vigabatrin
treatment affects 3-methoxytyrosine levels in plasma, urine,
or CSF. Therefore, analyzing multiple biomarkers at a time
could differentiate true disease signatures affecting disparate
pathways versus those biomarker signatures resultant through
treatment. In this study, the identification of medications
alongside the levels of 2-pyrrolidinone gave insight into the
mechanism of the elevation of 2-pyrolidinone as a clinical
biomarker (Figure 4). Further supporting the association
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of inhibition of GABA transaminase in the pathology of this
condition, the patients with GABA-transaminase deficiency all of
have some findings on imaging previously reported in patients
with vigabatrin toxicity (Figure 2). Patients 1, 3 and 4 have
bilateral T2 hyperintensities in the thalami. Patients 2 and 3 have
bilateral T2 hyperintensities in the dentate nucleus, and Patient 4
also has involvement of the brainstem, offering yet an additional
route to diagnosis of GABA-transaminase deficiency.
Metabolic biomarkers of disease accumulate to significantly
increased levels at points in pathways prior to the defective
enzymatic step. Consistent with this phenomenon, biochemicals
downstream of the affected enzyme decrease in abundance.
However, some biochemicals can be synthesized through
multiple mechanisms. For example, succinate can be formed
through amino acid catabolism, TCA cycle anaplerosis, and
oxidation of odd-chain fatty acids. Additionally, some mutations
in ABAT can express residual enzymatic activity and not a
complete ablation of enzymatic activity resulting in “partial”
decreases in metabolites downstream of ABAT (Pop et al., 2015).
As succinate also is formed downstream of ABAT activity,
and it is involved in mitochondrial physiology, a diagnosis of
GABA-transaminase deficiency needs to be differentiated from
mitochondrial diseases due to mutations in mitochondrial DNA
(Besse et al., 2015) or other aspects of mitochondrial physiology
(Ravasz et al., 2017). Building panels of biomarkers specific for an
increasing number of diverse diseases can help to further increase
the utility of biochemical phenotyping as a screening technology.
Biochemical phenotyping can differentiate signatures of
disease from those signatures of treatment associated with the
same biochemical pathway. Gathering additional samples from
other metabolic disorders and different therapeutic interventions
will help to strengthen this technology. Mutations in the genes
for GDH and succinic SSADH are associated with respective
IEMs. GDH deficiency can be responsive to vitamin B6 therapy
(Villela and Calcagnotto, 1977a,b). Early detection of disease
can result in expedited treatment, and this technology and
assay can then track effects of treatment (e.g., alleviation of
disease signatures) or track a how patients may respond to
treatment (e.g., differentiate responders from non-responders).
In the analysis of over 1,000 clinical samples, we identified
and confirmed two new cases of GABA-transaminase deficiency
(Patients 3 and 4), in addition to two previously described cases
(Patients 1 and 2). The patients presented exhibited phenotypic
variability with all having hypotonia, abnormal movements, and
eventually abnormal EEGs, but not all had seizures.
This broad screening tool can provide functional genomic data
to assess the pathogenicity of VUS and identify the biomarkers
of disease and, in the case of 2-pyrrolidinone, identify cases
where GABA metabolism is perturbed due to disease (GABA-
transaminase deficiency) or by pharmaceutical treatment that
affects GABA metabolism. While treatments which elevate 2-
pyrrolidinone levels through GABA-transaminase inhibition
can interfere with the use of 2-pyrrolidinone as a biomarker
for screening GABA-transaminase deficiency, the treatment of
patients with these drugs can be discerned from the patient
medical history, and many of these medications can also
be detected in clinical metabolomic analysis of plasma. As
mentioned in a preliminary case study citing clinical data and
interpretations from our clinical diagnostic platform (Koenig
and Bonnen, 2018), monitoring 2-pyrrolidinone and levels by
metabolomic profiling in patients with GABA-transaminase
deficiency may inform the efficacy of therapeutic intervention.
Here, we show that the integrated use of metabolomic and
genomic testing provides an informed approach to diagnose
GABA-transaminase deficiency and distinguish it from other
sources of GABA/2-pyrrolidinone elevations, that may be
otherwise confounding in targeted GABA analyses. These data
demonstrate the power of combining broad scale genotyping and
phenotyping technologies to diagnose inherited neurometabolic
disorders and indicate that metabolic phenotyping of plasma can
be used to screen for alterations in GABA metabolism due to
disease or as a consequence of treatment.
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